US Stocks: Biogen gets FDA approval for higher dose of genetic disorder drug, shares rise 3%

The U.S. Food and Drug Administration has approved a higher dose of Biogen’s spinal muscular atrophy ‌drug Spinraza, ⁠the company ⁠said on Monday, after rejecting it last year.